MONTREAL, QUEBEC--(Marketwire - January 28, 2008) - MethylGene Inc. (TSX: MYG), along with its collaborator Pharmion Corporation (NASDAQ: PHRM), today updated clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2008 Gastrointestinal Cancers Symposium in Orlando.
